Soy protein isoflavones do not reduce postmenopausal complications

doi:10.1136/bmj.329.7469.0-f

BMJ 2004;329 (2 October), doi:10.1136/bmj.329.7469.0-f

Filler

POEM^*

Soy protein isoflavones do not reduce postmenopausal complications

The first 150 words of the full text of this article appear below.

Question Do isoflavones improve cognitive function, bone mineraldensity, and plasma lipids in postmenopausal women?

Synopsis Recent trials have not shown a benefit of postmenopausaloestrogen in improving cognitive function, reducing cardiovascularcomplications, or maintaining long term protection against fractures.These authors evaluated whether naturally occurring plant isoflavones(phytoestrogens) can be used as an effective alternative fortraditional oestrogen therapy. They assigned 202 healthy postmenopausalwomen aged 60 to 75 years in a double blind fashion (uncertainallocation concealment) to receive 25.6 g of soy protein containing99 mg of isoflavones (52 mg genistein, 41 mg daidzein, and 6mg glycetein) or matching placebo on a daily basis for 12 months.Although not specifically stated in the manuscript, contactwith the authors clarified that outcomes were assessed by individualsblinded to treatment group assignment. Follow up was completefor 86% of the original participants. On intention to treatanalysis, cognitive . . . [Full text of this article]